Supplementary Figure S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

Key Points

• Blinatumomab shows potential benefit in the consolidation phase of chemotherapy for B-Cell precursor acute lymphoblastic leukemia.
• The study design includes specific pre-randomization chemotherapy cycles essential for treatment efficacy.
• Analysis of chemotherapy cycles emphasizes the drug's application in managing acute lymphoblastic leukemia.
• Understanding the study design aids in recognizing treatment pathways for B-Cell precursor leukemia patients.